Molecular targets for antiviral therapy of cytomegalovirus infections

Future Microbiology

Volumn 4, Issue 6, 2009, Pages 731-742

  Marschall, Manfred ^a   Stamminger, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antiviral; Cdk inhibitors; DNA replication; HCMV; Immediate early; Nucleoside analogs; PDGF receptor; Protein kinase inhibitors; UL97

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 1263W 94; ACICLOVIR; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CMX 001; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; GEFITINIB; HEXADECYLOXYPROPYLCIDOFOVIR; IMATINIB; IMMEDIATE EARLY PROTEIN; INDIRUBIN 3' MONOXIMER; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; NGIC 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; QUINAZOLINE DERIVATIVE; ROSCOVITINE; SMALL INTERFERING RNA; SORAFENIB; STAT2 PROTEIN; SUNITINIB; T 611; TOMEGLOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BRONCHIOLITIS OBLITERANS; CARCINOGENICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY GENE; INFECTION PREVENTION; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RETINITIS; REVIEW; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MODELS, BIOLOGICAL; PROTEINS; VIRAL PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 69849112712     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.40     Document Type: Review

References (78)

1. Griffiths PD: CMV as a cofactor enhancing progression of AIDS. J. Clin. Virol. 35(4), 489-492 (2006).
2. Adler SP, Nigro G, Pereira L: Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin. Perinatol. 31(1), 10-18 (2007).
3. Wolf DG, Lurain NS, Zuckerman T et al.: Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101(2), 463-465 (2003).
4. Mathy JE, Ma S, Compton T, Lin K: Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob. Agents Chemother. 52(9), 3267-3275 (2008).
5. Liu Z, Winkler M, Biegalke B: Human cytomegalovirus: host immune modulation by the viral US3 gene. Int. J. Biochem. Cell Biol. 41(3), 503-506 (2009).
6. Marshall EE, Bierle CJ, Brune W, Geballe AP: Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J. Virol. 83(9), 4112-4120 (2009).
7. Andoniou CE, Gli-Esposti MA: Insights into the mechanisms of CMV-mediated interference with cellular apoptosis. Immunol. Cell Biol. 84(1), 99-106 (2006).
8. Taylor RT, Bresnahan WA: Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced β interferon production. J. Virol. 79(6), 3873-3877 (2005).
9. Tavalai N, Stamminger T: New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783(11), 2207-2221 (2008).
10. Paulus C, Krauss S, Nevels M: A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl Acad. Sci. USA 103(10), 3840-3845 (2006).
11. Marchini A, Liu H, Zhu H: Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75(4), 1870-1878 (2001).
12. Kronschnabl M, Stamminger T: Synergistic induction of intercellular adhesion molecule-1 by the human cytomegalovirus transactivators IE2p86 and pp71 is mediated via an Sp1-binding site. J. Gen. Virol. 84(Pt 1), 61-73 (2003).
13. Scholz M, Doerr HW, Cinatl J: Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res. 49(3), 129-145 (2001).
14. Greaves RF, Mocarski ES: Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J. Virol. 72, 366-379 (1998).
15. Tavalai N, Papior P, Rechter S, Stamminger T: Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 82(1), 126-137 (2008).
16. Reboredo M, Greaves RF, Hahn G: Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication. J. Gen. Virol. 85(Pt 12), 3555-3567 (2004).
17. Patterson CE, Shenk T: Human cytomegalovirus UL36 protein is dispensable for viral replication in cultured cells. J. Virol. 73(9), 7126-7131 (1999).
18. Perry CM, Balfour JA: Fomivirsen. Drugs 57(3), 375-380 (1999).
19. Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM: Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42, 971-973 (1998).
20. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M: The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47(6), 804-811 (2008).
21. Luganini A, Caposio P, Mondini M, Landolfo S, Gribaudo G: New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. 105(6), 1791-1801 (2008).
22. Prichard MN, Gao N, Jairath S et al.: A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73(7), 5663-5670 (1999).
23. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES: Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl Acad. Sci. USA 98(4), 1895-1900 (2001).
24. Michel D, Mertens T: The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim. Biophys. Acta 1697(1-2), 169-180 (2004).
25. Marschall M, Marzi A, aus dem Siepen P et al.: Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem. 280(39), 33357-33367 (2005).
26. Milbradt J, Auerochs S, Sticht H, Marschall M: Cytomegaloviral proteins that associate with the nuclear lamina: components of a postulated nuclear egress complex. J. Gen. Virol. 90(Pt 3), 579-590 (2009).
27. Thomas M, Rechter S, Milbradt J et al.: Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. J. Gen. Virol. 90(Pt 3), 567-578 (2009).
28. Marschall M, Freitag M, Suchy P et al.: The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311(1), 60-71 (2003).
29. Schregel V, Auerochs S, Jochmann R, Maurer K, Stamminger T, Marschall M: Mapping of a self-interaction domain of the cytomegalovirus protein kinase pUL97. J. Gen. Virol. 88(Pt 2), 395-404 (2007).
30. Romaker D, Schregel V, Maurer K et al.: Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation. J. Med. Chem. 49(24), 7044-7053 (2006).
31. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T: Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 82(Pt 6), 1439-1450 (2001).
32. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF: Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320(5877), 797-799 (2008).
33. Schleiss M, Eickhoff J, Auerochs S et al.: Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res. 79(1), 49-61 (2008).
34. Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M: Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob. Agents Chemother. 48(11), 4154-4162 (2004).
35. Biron KK, Harvey RJ, Chamberlain SC et al.: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46(8), 2365-2372 (2002).
36. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T: Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 83(Pt 5), 1013-1023 (2002).
37. Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T: Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res. 48(1), 49-60 (2000).
38. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8(4), 303-306 (2003).
39. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD: Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann. Pharmacother. 42(10), 1447-1457 (2008).
40. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC: Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J. Virol. 77(21), 11499-11506 (2003).
41. Mercorelli B, Sinigalia E, Loregian A, Palu G: Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol. 18(3), 177-210 (2008).
42. Lyt-dependent DNA replication and formation of replication compartments in cotransfection assays. J. Virol. 70(11), 7398-7413 (1996).
43. Pari GS: Nuts and bolts of human cytomegalovirus lytic DNA replication. Curr. Top. Microbiol. Immunol. 325, 153-166 (2008).
44. Hwang JS, Kregler O, Schilf R et al.: Identification of acetylated, tetrahalogenated benzimidazole d-ribonucleosides with enhanced activity against human cytomegalovirus. J. Virol. 81(21), 11604-11611 (2007).
45. Dunn W, Chou C, Li H et al.: Functional profiling of a human cytomegalovirus genome. Proc. Natl Acad. Sci. USA 100(24), 14223-14228 (2003).
46. Oien NL, Brideau RJ, Hopkins TA et al.: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. 46(3), 724-730 (2002).
47. Lischka P, Zimmermann H: Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 8(5), 541-548 (2008).
48. Loregian A, Coen DM: Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol. 13(2), 191-200 (2006).
49. Ciesla SL, Trahan J, Wan WB et al.: Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59(3), 163-171 (2003).
50. Obaya AJ, Sedivy JM: Regulation of cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 59(1), 126-142 (2002).
51. Knockaert M, Greengard P, Meijer L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23(9), 417-425 (2002).
52. Rossignol M, Kolb-Cheynel I, Egly JM: Substrate specificity of the Cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO J. 16(7), 1628-1637 (1997).
53. Price DH: P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell Biol. 20(8), 2629-2634 (2000).
54. Kapasi AJ, Spector DH: Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases Cdk9 and Cdk7 at the viral transcriptosome. J. Virol. 82(1), 394-407 (2008).
55. Sanchez V, Spector DH: Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J. Virol. 80(12), 5886-5896 (2006).
56. Tamrakar S, Kapasi AJ, Spector DH: Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of Cdk9 and Cdk7. J. Virol. 79(24), 15477-15493 (2005).
57. Sanchez V, McElroy AK, Yen J et al.: Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 78(20), 11219-11232 (2004).
58. Bain M, Sinclair J: The S phase of the cell cycle and its perturbation by human cytomegalovirus. Rev. Med. Virol. 17(6), 423-434 (2007).
59. Sanchez V, McElroy AK, Spector DH: Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. J. Virol. 77(24), 13214-13224 (2003).
60. Schang LM, St Vincent MR, Lacasse JJ: Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 17(6), 293-320 (2006).
61. Rechter S, Scott GM, Eickhoff J et al.: Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J. Biol. Chem. 284(13), 8605-8613 (2009).
62. Herget T, Marschall M: Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors. In: New Concepts of Antiviral Therapy. Holzenburg A, Bogner E (Eds). Springer, Berlin, Germany, 351-371 (2006).
63. Heredia A, Davis C, Bamba D et al.: Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19(18), 2087-2095 (2005).
64. Canduri F, Perez PC, Caceres RA, de Azevedo WF: CDK9 a potential target for drug development. Med. Chem. 4(3), 210-218 (2008).
65. Orzaez M, Gortat A, Mondragon L, Bachs O, Perez-Paya E: ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem 4(1), 19-24 (2009).
66. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79(4), 1283-1316 (1999).
67. Thyberg J: Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol. Histopathol. 13(3), 871-891 (1998).
68. Reinhardt B, Mertens T, Mayr-Beyrle U et al.: HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF β-receptor. Cardiovasc. Res. 67(1), 151-160 (2005).
69. Gredmark S, Straat K, Homman-Loudiyi M, Kannisto K, Soderberg-Naucler C: Human cytomegalovirus downregulates expression of receptors for platelet-derived growth factor by smooth muscle cells. J. Virol. 81(10), 5112-5120 (2007).
70. Zhou YF, Yu ZX, Wanishsawad C, Shou M, Epstein SE: The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF β-receptor. Biochem. Biophys. Res. Commun. 256(3), 608-613 (1999).
71. Tikkanen JM, Lemstrom K, Koskinen PK: Blockade of PDGF receptor protein-tyrosine kinase activity effectively inhibits development of rat CMV infection enhanced experimental obliterative bronchiolitis. J. Heart Lung Transplant. 20(2), 167 (2001).
72. Soroceanu L, Akhavan A, Cobbs CS: Platelet-derived growth factor-a receptor activation is required for human cytomegalovirus infection. Nature 455(7211), 391-395 (2008).
73. Bauman JE, Eaton KD, Martins RG: Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin. Cancer Res. 13(15 Pt 2), S4632-S4636 (2007).
74. Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69(2), 223-240 (2009).
75. Petrelli A, Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15(5), 422-432 (2008).
76. Yurochko AD: Human cytomegalovirus modulation of signal transduction. Curr. Top. Microbiol. Immunol. 325, 205-220 (2008).
77. Kaspari M, Tavalai N, Stamminger T, Zimmermann A, Schilf R, Bogner E: Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus. FEBS Lett. 582(5), 666-672 (2008).
78. Vischer HF, Hulshof JW, de Esch IJP, Smit MJ, Leurs R: Virus-encoded G-protein-coupled receptors: constitutively active (dys)regulators of cell function and their potential as drug target. Ernst Schering Found. Symp. Proc. (2), 187-209 (2006).